Awards
2024 P30 Pilot & Feasibility Award RFA
The Center for Skeletal Research (CSR), funded by the National Institute of Artritis and Musculoskeletal Diseases (NIAMS), is announcing a request for Pilot and Feasibility Research proposals ($35,000/year) The Awardees will be expected to present progress to CSR members biannually and provide a written annual report. Basic, translational, and clinical studies are welcome, though no clinical trials are allowed. Prior CSR P&F awardees are not eligible.
LOI due August 19, 2024
.
Light-seq Spatial Transcriptomics RFA
The RNA sequencing and spatial transcriptomics core has a request for application (RFA) for Light-Seq spatial transcriptomics projects from CSR members Light-seq captures up to 4 different cell types of interest or 4 different regions of interest in tissue sections.
Technical support and supply costs will be provided for murine projects that involve non-mineralized musculoskeletal tissues (e.g., tendon, ligament, cartilage, synovium, muscle, embryonic musculoskeletal elements); the core is still developing Light-Seq for mineralized tissues.
Questions about Light-Seq in general, and this RFA specifically, can be sent to Dr. Matthew Warman (matthew.warman@childrens.harvard.edu).
.
Clinical Phenotyping Core Mini-grant RFA
Mini-grants of up to $10,000 are available to support the acquisition of critical preliminary data for grant submission or the use of clinical phenotyping to support existing work for a manuscript submission. Funds must be used for services provided by the Clinical Phenotyping Core (CPC; https://csr-mgh.org/cores/clinical-phenotyping-core-2/). Awarded funds will cover essential efforts at the CPC including personnel support for conducting the analyses. Please contact Dr. Ata Kiapour (ata.kiapour@childrens.harvard.edu) to discuss opportunities and advantages to using CPC services to support your ongoing and future research programs.
Directed Differentiation Core Mini-grant RFA
Mini-grants of up to $10,000 are available to support the acquisition of critical preliminary data for grant submission. Funds must be used for services provided by the Directed Differentiation Core (DDC). Awarded funds will cover essential lot-tested cell culture reagents and consumables in the core, and other associated experimental costs. Please contact Dr. April Craft (april.craft@childrens.harvard.edu) to discuss opportunities and advantages to using DDC services to support your ongoing and future research programs.
.
CSR Core Mini Grants
Center for Musculoskeletal Research Core mini-grants (up to $2,000 direct costs only) will be awarded for the purpose of obtaining critical preliminary data for an upcoming grant submission. Funds must be used for CSR Core services.
.
Innovation Awards
Innovation awards are designed to promote the ability of Center investigators to visit outside laboratories to gain expertise in novel methodologies which can be integrated into one of the Resource Cores so our community can benefit from these new technologies. Funds (up to $5000) are available to cover the costs of supplies and reagents required, as well as any necessary travel. Applications are accepted on a rolling basis. Discussion with the relevant Core director is highly encouraged prior to preparing an application.
P&F Awardees
| PI | TITLE OF PILOT AND FEASIBILITY PROJECT |
| 2023 | |
| Qian Cong, PhD
(HSDM) |
Stem cells and committed muscle cells reprogram in heterotopic ossification dependent of inflammation |
| Lamya Karim, PhD
(UMass Dartmouth) |
Impact of irisin on glycation in bone tissue and cells |
| David Maridas, PhD
(HSDM) |
The role of Smad1/5/8 signaling in the postnatal skeleton |
| 2022 | |
| Beth Bragdon, PhD
(BUSM, Orth) |
The Effect of Type 2 Diabetes on Skeletal Stem Cell Response to Injury |
| Fjola Johannesdottir, PhD
(BIDMC, Orth) |
Influence of Trunk Muscle and Vertebral Bone Deficits on Fracture Risk in Type 1 Diabetes |
| Tadatoshi Sato, PhD
(UMass) |
Development of rAAV Gene Therapy for Osteogenesis Imperfecta |
| 2021 | |
| Susan MacLauchlan, PhD
(BWH, Rheum) |
The role of TET2-mediated clonal hematopoiesis in osteoporosis |
| Brianne Connizzo, PhD
(BUSM, Engineering) |
An In Vivo Model of Inflammation-Based Joint Damage to Study Bone-Tendon Interactions |
| Nora Renthal, MD, PhD
(BCH, Endo) |
Functional genomic screening to expedite gene discovery in growth plate chondrocytes |
| Petra Simic, MD, PhD
(MGH, Renal) |
Glycerol-3-phosphate acyltransferase-2 regulates FGF23 in acute kidney injury |
| 2020 | |
| Christian Jacome-Galarza
(BWH, Rheum) |
Title Cellular origins and functions of osteoclasts precursors in arthritis |
| Masao Kaneki
(MGH, Pain Med) |
Targeting myostatin-activin type 2 receptor pathway prevents burn injury-induced bone loss |
| Jessica Lehoczky
(BWH, Orth) |
ANCHORING LGR6 TO OSTEOGENESIS |
| 2019 | |
| Eva S. Liu, M.D.
(BWH, Endo) |
Role of 1, 25 dihydroxyvitamin D in the development of enthesopathy in X-linked hypophosphatemia |
| Michael B. Albro, M.S., Ph.D.
(BU, Engineering) |
Targeted Inhibition of Pathogenic TGF-beta Activity in Osteoarthritis |
| 2018 | |
| Diana L. Carlone, Ph.D.
(BCH, Endo) |
Cfp1 Action in Chondrogenesis |
| LI Zeng, Ph.D.
(Tufts) |
The Role of T lymphocytes in Osteoarthritis Progression |
| 2017 | |
| Frank Ko, Ph.D.
(MGH, Endo) |
The effects of caloric restriction on bone formation and mTOR signaling |
| Michaela Reagan, Ph.D.
(MMCRI) |
Targeting sclerostin in multiple myeloma-induced bone disease |
| 2016 | |
| Keertik Fulzele, Ph.D.
(BUSM, Dental) |
Metabolic effect of bone secreted Wnt-signaling inhibitor sclerostin |
| Marc Wein, M.D., Ph.D.
(MGH, Endo) |
Control of osteocyte biology by salt inducible kinases |
| 2015 | |
| (Year 2) Agnes Berendsen, Ph.D.
(HSDM) |
VEGF-dependent control of osteoblast/adipocyte differentiation |
| Jenna Galloway, Ph.D.
(MGH, Orth) |
A zebrafish model of tendon-bone attachment injury and regeneration |
| 2014 | |
| Agnes Berendsen, Ph.D.
(HSDM) |
VEGF-dependent control of osteoblast/adipocyte differentiation |
| Melissa Putman, M.D.
(BCH, Endo) |
Whole body vibration to prevent the musculoskeletal complications of immobility |